Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apretude
Pharma
Uptake of Gilead's Yeztugo will be swift, analyst says
A HIV physician expects a “majority” of her 125 PrEP users will switch to Gilead's newly approved Yeztugo within the next 12 months.
Kevin Dunleavy
Jun 25, 2025 2:51pm
GSK questions Gilead's potential dominance of the PrEP market
Feb 6, 2025 2:20pm
GSK bolsters case for long-acting HIV PrEP drug Apretude
Oct 16, 2024 1:26pm
GSK to triple long-acting Apretude supply to boost global access
Oct 7, 2024 10:56am
Gilead races toward filings for long-acting PrEP after trial win
Sep 12, 2024 11:45am
MSF calls out GSK's ViiV for nondisclosure clauses in contract
Aug 17, 2023 2:54pm
